Central nervous system (CNS) damage leads to persistent loss of cognition, sensation, and
motor control, and affecting approximately millions of patients. Retention or regain of …

Nanocarrier drug delivery systems are attractive options for targeted delivery of survival-and
regeneration-enhancing therapeutics to neurons damaged by degenerative or traumatic …

Cell-selective drug release in the central nervous system (CNS) holds great promise for the
treatment of many CNS disorders but it is still challenging. We previously demonstrated that …

There are approximately 1.5 million people who experience traumatic injuries to the brain
and 265,000 who experience traumatic injuries to the spinal cord each year in the United …

We induced tissue repair following ischemic stroke in rats by delivering brain-derived
neurotrophic factor (BDNF) directly to the brain. This protein is a potent modulator of …

Neurodegenerative diseases represent a major public health problem, but beneficial clinical
treatment with neurotrophic factors has not been established yet. The therapeutic use of …

Targeted drug delivery to specific neural cells within the central nervous system (CNS) plays
important roles in treating neurological disorders, such as neurodegenerative (eg, targeting …

Drug delivery requires precision in timing, location, and dosage to achieve therapeutic
benefits. Challenges in addressing all three of these critical criteria result in poor temporal …

This article describes a new approach in targeted drug delivery to the central nervous
system (CNS) in a significant departure from the predominant systematic drug administration …

Spinal cord injury (SCI) causes neuronal death and leads to persistent loss of motor and
sensory functions. Treatment of SCI is challenging as axon regeneration from damaged …